Have you changed your practice in treating CRAO with IV thrombolysis?

The recent THEIA trial had a limited sample size to draw conclusions, even though there was a non-significant trend of improved visual acuity initially in the thrombolysis group. Even the TenCRAOS trial had a small sample size with recruitment challenges, where subtle small differences cannot be acc...

Recent clinical trials have not supported the use of IV tPA or tenecteplase in CRAO, and our institution has stopped recommending it.

Agree with the points above. One layer that often gets missed in these discussions is logistics. These patients are usually first seen by ED or neurology, and comfort with the acute ocular exam and excluding mimics isn't uniform across settings. Ophthalmology can sort that out, but availability in t...

Perhaps what was most evident from the recently published TenCRAOS was how well the control group did. That was unexpected to me, uncovering a bias that I had in favour of treatment. The trial was small in total N. There is a larger trial ongoing in this space, which will provide more information. C...